Mabwell Biotechnology
http://www.maiweibio.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mabwell Biotechnology
Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives
Public Company Edition: Aileron, Talaris and Frequency said they will reduce expenses and seek options for maximizing shareholder returns under tough stock market conditions. However, CureVac and Supernus are among firms recently able to access new cash – $250m and $150m, respectively.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Miscellaneous
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Jiangsu T-mab BioPharma Co., Ltd.
- Maiwei (Shanghai) Biotechnology, Mabwell (Shanghai) Bioscience Co. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mabwell Biotechnology
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice